Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

N. Moore, Kathleen; Angelergues, Antoine; E. Konecny, Gottfried; García García, Yolanda; Banerjee, Susana; Lorusso, Domenica; Lee, Jung‐Yun; W. Moroney, John; Colombo, Nicoletta; Roszak, A.; M. Tromp, Jacqueline; Myers, Tashanna; Lee, Jeong‐Won; Beiner, Mario; Cosgrove, Casey; Cibula, David; P. Martin, Lainie; Sabatier, Renaud; Buscema, Joseph; Estévez-García, Purificación; Coffman, Lan; Nicum, Shibani; Duska, Linda; Pignata, Sandro; Gálvez, Fernando; Wang, Yuemei; Method, Michael; Berkenblit, Anna; Bello Roufai, Diana; Van Gorp, Toon

doi:10.1056/nejmoa2309169

Public

Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer

Published in New England Journal of Medicine • Dec 6, 2023

Authors:

Kathleen N. Moore

Antoine Angelergues

Gottfried E. Konecny

Abstract

BACKGROUND: Mirvetuximab soravtansine-gynx (MIRV), a first-in-class antibody-drug conjugate targeting folate receptor α (FRα), is approved for the treatment of platinum-resistant ovarian cancer in the United States. METHODS: We conducted a phase 3, global, confirmatory, open-label, randomized, contr...

Subject

Medicine

Internal medicine

Chemotherapy

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!